Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Irinotecan for children with relapsed solid tumors.

Toshiji Shitara1, Akira Shimada, Ryoji Hanada

  • 1Department of Hematology/Oncology, Gunma Children's Medical Center, Seta-gun, Gunma, Japan. shitara@gcmc.pref.gunma.jp

Pediatric Hematology and Oncology
|May 3, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The first epidemiological study of presymptomatic type 1 diabetes among first-degree relatives in Japan: PREP-T1D study.

Diabetes research and clinical practice·2026
Same author

Clinical Characteristics and Outcomes of Acute Megakaryoblastic Leukemia With t(1;22)(p13;q13) in Children.

Pediatric blood & cancer·2026
Same author

Clinical and molecular characterization of thrombocytosis in transient abnormal myelopoiesis.

Leukemia·2026
Same author

Sex differences in the impact of structured education together with isCGM in individuals with type 1 diabetes:post hoc analysis of the ISCHIA study.

The journal of medical investigation : JMI·2026
Same author

Life-threatening acute complications persist among individuals with type 1 diabetes in Japan: A nationwide registry-based cross-sectional study.

Journal of diabetes investigation·2026
Same author

A Non-Fetal Chronic Residual Inflammatory Liver Phenotype After Transient Abnormal Myelopoiesis in Down Syndrome.

Pediatric blood & cancer·2026

Irinotecan shows promise as a new treatment for childhood solid tumors. In a study, over 30% of children with relapsed tumors experienced partial response to this chemotherapy drug.

Area of Science:

  • Pediatric Oncology
  • Medical Oncology
  • Pharmacology

Background:

  • Childhood solid tumors represent a significant challenge in pediatric oncology.
  • Limited effective treatment options exist for relapsed pediatric solid tumors.

Purpose of the Study:

  • To evaluate the efficacy and safety of irinotecan in children with relapsed solid tumors.
  • To determine the potential role of irinotecan in first-line treatment regimens.

Main Methods:

  • A phase II clinical trial involving sixteen children with relapsed solid tumors.
  • Patients received irinotecan at a dose of 180 mg/m2/day for 3 consecutive days, with cycles repeated after a 25-day break.
  • Tumor types included neuroblastoma, rhabdomyosarcoma, nephroblastoma, undifferentiated sarcoma, primitive neuroectodermal tumor, and leiomyosarcoma.

Related Experiment Videos

Main Results:

  • Partial response was observed in 5 out of 16 patients (31.3%), across various tumor types.
  • A decrease in tumor markers was noted in an additional 2 patients.
  • The average age of the pediatric participants was 6 years.

Conclusions:

  • Irinotecan demonstrates promising activity in pediatric patients with relapsed solid tumors.
  • Further investigation into irinotecan as a component of first-line therapy for these cancers is warranted.